Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | Director | February 28, 2020 | May 01, 2020 |
| BioAge Labs, Inc.BIOA · Entity 5569 | Chief Financial Officer | April 23, 2026 | April 24, 2026 |
| Coya Therapeutics, Inc.COYA · Entity 6727 | Director | January 02, 2026 | January 07, 2026 |
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | Director | June 06, 2018 | June 08, 2018 |
| Gain Therapeutics, Inc.GANX · Entity 6943 | Director | July 15, 2026 | July 17, 2026 |
| MELINTA THERAPEUTICS, INC. /NEW/CEMP · Entity 154249 | Director | March 07, 2017 | March 09, 2017 |
| NeuBase Therapeutics, Inc.NBSE · Entity 109568 | Director | September 09, 2022 | September 12, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date February 28, 2020 · Filed May 01, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,500 |
Reported balance
After 2020-02-28 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2020-02-28 · Grant · Acquired 7,500 · Balance 7,500 F1: These shares represent restricted stock units ("RSUs"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.
BioAge Labs, Inc.
Report date April 23, 2026 · Filed April 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,575 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Exercise / conversion · Acquired 3,542 · Balance 36,575 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.38 · Expires 2035-02-17 | Direct | 155,833 |
Reported balance
After 2026-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-23 · Exercise / conversion · Disposed 3,542 · Balance 155,833 F1: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Coya Therapeutics, Inc.
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2036-01-02 | Direct | 10,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 10,000 · Balance 10,000 F1: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant.
Esperion Therapeutics, Inc.
Report date June 06, 2018 · Filed June 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47 |
Ending reported balance
After 2018-06-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-06-06 · Exercise / conversion · Acquired 5,000 · Balance 5,047 F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Row 2 · 2018-06-06 · Exercise / conversion · Acquired 8,000 · Balance 13,047 F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Row 3 · 2018-06-06 · Other · Disposed 5,000 · Balance 8,047 F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Row 4 · 2018-06-06 · Other · Disposed 8,000 · Balance 47 F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.42 · Expires 2024-05-15 | Direct | 0 |
Reported balance
After 2018-06-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-06-06 · Exercise / conversion · Acquired 5,000 · Balance 0 F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.75 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2018-06-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-06-06 · Exercise / conversion · Acquired 8,000 · Balance 0 F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein.
Gain Therapeutics, Inc.
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2036-07-15 | Direct | 25,000 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.
MELINTA THERAPEUTICS, INC. /NEW/
Report date March 07, 2017 · Filed March 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Aisling Capital II, LP | 0 |
Last balance in matching sequence
After 2017-03-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-03-07 · Sale · Disposed 50,100 · Balance 99,900 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F3: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Row 2 · 2017-03-08 · Sale · Disposed 99,900 · Balance 0 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F3: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 95 |
Reported balance
Holding disclosure · report date 2017-03-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 95 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
NeuBase Therapeutics, Inc.
Report date September 09, 2022 · Filed September 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2032-09-09 | Direct | 37,600 |
Reported balance
After 2022-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-09 · Grant · Acquired 37,600 · Balance 37,600 F1: 25% of the total shares shall vest on the first anniversary of September 9, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the total shares shall vest on the first anniversary of September 9, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 12:33 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001104659-26-084439 · tm2620629-6_4seq1.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-07-15 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:19 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,542 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001120478-26-000013 · form4-04242026_080410.xml · derivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,833 Underlying: Common Stock · 3,542 shares Expires 2035-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:19 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 3,542 | $4.38 | $15,513.96 |
DisclosureSEC source: 0001120478-26-000013 · form4-04242026_080410.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:44 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,542 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001120478-26-000011 · form4-03032026_090347.xml · derivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,375 Underlying: Common Stock · 3,542 shares Expires 2035-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:44 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 3,542 | $4.38 | $15,513.96 |
DisclosureSEC source: 0001120478-26-000011 · form4-03032026_090347.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:38 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001120478-26-000009 · form4-02192026_090219.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:23 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,541 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001120478-26-000007 · form4-02032026_090256.xml · derivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,917 Underlying: Common Stock · 3,541 shares Expires 2035-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:23 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 3,541 | $4.38 | $15,509.58 |
DisclosureSEC source: 0001120478-26-000007 · form4-02032026_090256.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:20 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,542 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001120478-26-000005 · form4-01212026_090153.xml · derivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,458 Underlying: Common Stock · 3,542 shares Expires 2035-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:20 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 3,542 | $4.38 | $15,513.96 |
DisclosureSEC source: 0001120478-26-000005 · form4-01212026_090153.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:22 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001120478-26-000003 · form4-01152026_090117.xml · derivative · entry 6 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,587 Underlying: Common Stock · 27,000 shares Expires 2034-04-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024. F6 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:22 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 1,923 | $21.08 | $40,538.38 |
DisclosureSEC source: 0001120478-26-000003 · form4-01152026_090117.xml · nonDerivative · entry 5 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,408 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.04 to $21.15 per share, inclusive. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:22 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 11,663 | $20.54 | $239,548.69 |
DisclosureSEC source: 0001120478-26-000003 · form4-01152026_090117.xml · nonDerivative · entry 4 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,331 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $21.02 per share, inclusive. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:22 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 4,440 | $19.45 | $86,369.54 |
DisclosureSEC source: 0001120478-26-000003 · form4-01152026_090117.xml · nonDerivative · entry 3 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,994 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.86 per share, inclusive. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:22 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 8,974 | $18.43 | $165,371.08 |
DisclosureSEC source: 0001120478-26-000003 · form4-01152026_090117.xml · nonDerivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,434 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:22 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 27,000 | $8.39 | $226,530.00 |
DisclosureSEC source: 0001120478-26-000003 · form4-01152026_090117.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:27 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0001193125-26-005023 · ownership.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, par value $0.0001 per share · 10,000 shares Expires 2036-01-02 F1 · derivative.exercise_date: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 20:01 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | Exercise / conversionStock Option (right to buy) · Derivative | 17,557 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001641172-25-024820 · ownership.xml · derivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,557 shares Expires 2031-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 20:01 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | Exercise / conversionCommon Stock, par value $0.0001 per share | 17,557 | $1.09 | $19,137.13 |
DisclosureSEC source: 0001641172-25-024820 · ownership.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2025 Filed Jun 25, 2025 21:30 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001641172-25-016536 · ownership.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2025, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 02:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0000950170-25-027253 · ownership.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock, par value $0.0001 per share · 5,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:19 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001415889-25-004859 · form4-02202025_090258.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| January 01, 2025 Filed Jan 4, 2025 02:31 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0000950170-25-001571 · ownership.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock, par value $0.0001 per share · 5,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. Read SEC document |
| June 24, 2024 Filed Jun 27, 2024 01:30 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001493152-24-025338 · ownership.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 24, 2024, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| January 01, 2024 Filed Jan 19, 2024 23:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001493152-24-003110 · ownership.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock, par value $0.0001 per share · 5,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:38 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001209191-23-039723 · doc4.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2033-06-23 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments commencing on July 23, 2023, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 13:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseWarrant to Purchase Common Stock · Derivative | 5,000 | Not disclosed Strike: $7.50 | Not disclosed |
DisclosureSEC source: 0001493152-23-000221 · ownership.xml · derivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock, par value $0.0001 per share · 5,000 shares Expires 2025-01-03 F1 · price: Reporting Person purchased 10,000 shares of Common Stock and an accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 13:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseCommon Stock, par value $0.0001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-000221 · ownership.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: Reporting Person purchased 10,000 shares of Common Stock and an accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:10 UTC | Gain Therapeutics, Inc. GANX · Entity 6943 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-22-051010 · doc4.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2032-09-20 F1 · derivative.exercise_date: The option vests fully on the day before the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 21:00 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | GrantStock option (right to buy) · Derivative | 37,600 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001104659-22-099286 · tm2225655-2_4seq1.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,600 Underlying: Common Stock · 37,600 shares Expires 2032-09-09 F1 · derivative.exercise_date: 25% of the total shares shall vest on the first anniversary of September 9, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months. Read SEC document |
| August 19, 2021 Filed Sep 17, 2021 20:17 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | GrantStock option (right to buy) · Derivative | 38,135 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0001104659-21-116925 · tm2127926-3_4seq1.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,135 Underlying: Common Stock · 38,135 shares Expires 2031-08-19 F1 · derivative.exercise_date: 25% of the total shares shall vest on the first anniversary of August 19, 2021, and the remaining shares shall vest on an equal monthly basis over the following 36 months. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 15:03 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | PurchaseCommon Stock | 8,000 | $4.75 | $38,000.00 |
DisclosureSEC source: 0001104659-21-083253 · tm2120227-1_4seq1.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · ownership.direct: The power of attorney under which this form was signed is on file with the Commission. Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 20:02 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | PurchaseCommon Stock | 12,000 | $5.00 | $60,000.00 |
DisclosureSEC source: 0001104659-21-055580 · tm2114321-2_4seq1.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 F1 · ownership.direct: The power of attorney under which this form was signed is on file with the Commission. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 21:20 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | GrantStock option (right to buy) · Derivative | 14,634 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001104659-20-104493 · tm2030658d4_4.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,634 Underlying: Common Stock · 14,634 shares Expires 2030-09-09 F1 · derivative.exercise_date: 25% of the total shares shall vest on the first anniversary of September 9, 2020, and the remaining shares shall vest on an equal monthly basis over the following 36 months. Read SEC document |
| April 30, 2020 Filed May 4, 2020 18:18 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | PurchaseCommon Stock | 10,000 | $6.00 | $60,000.00 |
DisclosureSEC source: 0001104659-20-056110 · tm2018429-2_form4.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · ownership.direct: The power of attorney under which this form was signed is on file with the Commission. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:11 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001193805-20-000291 · e619425_4-goldstein.xml · derivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-02-28 F2 · derivative.exercise_date: The option vests in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:11 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-20-000291 · e619425_4-goldstein.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: These shares represent restricted stock units ("RSUs"), which will vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F1 · balance_after: These shares represent restricted stock units ("RSUs"), which will vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. Read SEC document |
| February 28, 2020 Filed May 1, 2020 21:11 UTC Amendment | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-20-000551 · e619597_4a-goldstein.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: These shares represent restricted stock units ("RSUs"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F1 · balance_after: These shares represent restricted stock units ("RSUs"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. Read SEC document |
| July 12, 2019 Filed Jul 17, 2019 00:33 UTC | NeuBase Therapeutics, Inc. NBSE · Entity 109568 | GrantStock option (right to buy) · Derivative | 227,330 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0001387131-19-005129 · ownership.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,330 Underlying: Common stock · 227,330 shares Expires 2029-07-12 F1 · derivative.exercise_date: 1/36th of the total shares subject to the option shall vest monthly over three years. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.89 | $0.00 |
DisclosureSEC source: 0001193805-19-000296 · e618305_4-goldstein.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-03-13 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) March 13, 2029 and (ii) the one-year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| June 22, 2018 Filed Jun 25, 2018 21:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001193805-18-000904 · e618129_4-goldstein.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2028-06-22 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 22, 2028 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:08 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.75 | $0.00 |
DisclosureSEC source: 0001179110-18-008309 · edgar.xml · derivative · entry 6 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2026-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:08 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $14.42 | $0.00 |
DisclosureSEC source: 0001179110-18-008309 · edgar.xml · derivative · entry 5 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:08 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | OtherCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008309 · edgar.xml · nonDerivative · entry 4 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47 F1 · kind: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:08 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | OtherCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-008309 · edgar.xml · nonDerivative · entry 3 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,047 F1 · kind: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:08 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Exercise / conversionCommon Stock | 8,000 | $17.75 | $142,000.00 |
DisclosureSEC source: 0001179110-18-008309 · edgar.xml · nonDerivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:08 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Exercise / conversionCommon Stock | 5,000 | $14.42 | $72,100.00 |
DisclosureSEC source: 0001179110-18-008309 · edgar.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:18 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 10,100 | $0.00 Strike: $38.32 | $0.00 |
DisclosureSEC source: 0001179110-18-007561 · edgar.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Underlying: Common Stock · 10,100 shares Expires 2028-05-23 F1 · derivative.exercise_date: The options vest in full on the earlier of (i) May 23, 2019 and (ii) the Issuer's next annual meeting of stockholders following May 23, 2018. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 22:53 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Exercise / conversionStock Option (right to buy) · Derivative | 21,471 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-17-015732 · edgar.xml · derivative · entry 3 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,471 shares Expires 2023-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 22:53 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | OtherCommon Stock | 21,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015732 · edgar.xml · nonDerivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47 F1 · kind: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.